Recombinant
RabMAb

Recombinant Anti-TPA Tissue Plasminogen Activator antibody [EPR7232(2)] (ab157469)

Overview

  • Product name

    Anti-TPA Tissue Plasminogen Activator antibody [EPR7232(2)]
    See all TPA Tissue Plasminogen Activator primary antibodies
  • Description

    Rabbit monoclonal [EPR7232(2)] to TPA Tissue Plasminogen Activator
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: IP
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    corresponding to Human TPA Tissue Plasminogen Activator.

  • Positive control

    • WB: Mouse plasma, Rat plasma, Human plasma, and Human liver lysates; IHC-P: human lung carcinoma, cervical carcinoma, skeletal muscle, brain, kidney and liver tissue, mouse and rat liver tissue
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab157469 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/5000. Predicted molecular weight: 63 kDa.
IHC-P 1/100 - 1/1000.

See IHC antigen retrieval protocols.

  • Application notes
    Is unsuitable for IP.
  • Target

    • Function

      Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Play a direct role in facilitating neuronal migration.
    • Tissue specificity

      Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
    • Involvement in disease

      Note=Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
    • Sequence similarities

      Belongs to the peptidase S1 family.
      Contains 1 EGF-like domain.
      Contains 1 fibronectin type-I domain.
      Contains 2 kringle domains.
      Contains 1 peptidase S1 domain.
    • Domain

      Both FN1 and one of the kringle domains are required for binding to fibrin.
      Both FN1 and EGF-like domains are important for binding to LRP1.
      The FN1 domain mediates binding to annexin A2.
      The second kringle domain is implicated in binding to cytokeratin-8 and to the endothelial cell surface binding site.
    • Post-translational
      modifications

      The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.
      Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.
      N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.
      Characterization of O-linked glycan was studied in Bowes melanoma cell line.
    • Cellular localization

      Secreted > extracellular space.
    • Information by UniProt
    • Database links

    • Alternative names

      • Alteplase antibody
      • DKFZp686I03148 antibody
      • Plasminogen activator tissue antibody
      • Plasminogen activator tissue type antibody
      • PLAT antibody
      • Reteplase antibody
      • t PA antibody
      • T Plasminogen Activator antibody
      • t-PA antibody
      • T-plasminogen activator antibody
      • Tissue plasminogen activator (t PA) antibody
      • Tissue type plasminogen activator antibody
      • Tissue-type plasminogen activator chain B antibody
      • tPA antibody
      • TPA_HUMAN antibody
      • TPA1 antibody
      see all

    Images

    • All lanes : Anti-TPA Tissue Plasminogen Activator antibody [EPR7232(2)] (ab157469) at 1/1000 dilution (Purified)

      Lane 1 : Mouse plasma lysates
      Lane 2 : Rat plasma lysates
      Lane 3 : Human plasma lysates
      Lane 4 : Human brain lysates
      Lane 5 : Human heart lysates
      Lane 6 : Human liver lysates

      Lysates/proteins at 15 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size: 63 kDa
      Observed band size: 68 kDa
      why is the actual band size different from the predicted?



      T-PA is serected and mainly released into blood and extracellular fluid to activate plasminogen. The molecular weight observed is consistent with what has been described in PMID: 22069469

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of rat liver tissue sections labeling TPA Tissue Plasminogen Activator with purified ab157469 at 1/1000 dilution (1.91 µg/ml). Heat mediated antigen retrieval was performed Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0). Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of mouse liver tissue sections labeling TPA Tissue Plasminogen Activator with purified ab157469 at 1/1000 dilution (1.91 µg/ml). Heat mediated antigen retrieval was performed Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0). Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human lung carcinoma tissue sections labeling TPA Tissue Plasminogen Activator with purified ab157469 at 1/1000 dilution (1.91 µg/ml). Heat mediated antigen retrieval was performed Heat mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0). Rabbit specific IHC polymer detection kit HRP/DAB (ab209101) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
    • ab157469 (unpurified) showing +ve staining in Human normal liver.

    • ab157469 (unpurified) showing +ve staining in Human normal kidney.

    • ab157469 (unpurified) showing +ve staining in Human normal brain.

    • ab157469 (unpurified) showing +ve staining in Human skeletal muscle.

    • Anti-TPA Tissue Plasminogen Activator antibody [EPR7232(2)] (ab157469) at 1/1000 dilution (unpurified) + Human plasma lysate at 10 µg

      Secondary
      HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 63 kDa

    • Immunohistochemical analysis of paraffin-embedded Human cervial carcinoma tissue labeling TPA Tissue Plasminogen Activator with ab157469 (unpurified) 1/100 dilution.

    • Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling TPA Tissue Plasminogen Activator with ab157469  (unpurified) at 1/100 dilution.

    References

    This product has been referenced in:

    • Cheng M  et al. Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer. Oncol Lett 16:4400-4406 (2018). Read more (PubMed: 30250539) »
    • Li YB  et al. miR-199a-3p is involved in the pathogenesis and progression of diabetic neuropathy through downregulation of SerpinE2. Mol Med Rep 16:2417-2424 (2017). Read more (PubMed: 28677735) »
    See all 3 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab157469.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up